Analyst Consensus ?
ConsensusHold22 ratings
Bullish1045.5%
Neutral1150.0%
Bearish14.5%
DaVita Inc. · DVA · FY2025 Q3 · Calendar Q4 2025
DaVita Reaffirms Guidance as Volume Headwinds Persist
The supplied analysis supports a mixed picture: DaVita’s reaffirmed guidance and technology, AI, and clinical-research initiatives provide support, but declining treatment volume, an IKC operating loss, and policy and payer-mix uncertainty limit confidence in a straightforward growth case.
Reported After market closeNYSEHealthcare
$11.47B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.51
Consensus $3.17
EPS surprise
-20.8%
Reported versus consensus
Reported revenue
$3.42B
Consensus $3.43B
Revenue surprise
-0.2%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-6.2%
Event window
SPY move
-1.1%
Same window
Abnormal move
-5.1%
Stock minus SPY
Volume
3.9×
Versus trailing sessions
Subsequent drift
+0.8%
Up to 20 sessions
DVASPY benchmark
Ask FN2 about DVA FY2025 Q3
Transcript, numbers and history already loaded
Why did DVA fall 6.2% after missing EPS estimates in FY2025 Q3?What changed in DVA's guidance and outlook in FY2025 Q3?Give me the bull and bear case for DVA after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis says Q3 results met expectations and full-year guidance was reaffirmed, while volume declined 1.5% year over year. It also highlights continued technology and AI investment, a $21 million adjusted IKC operating loss, and ongoing uncertainty around revenue recognition.
Guidance delta
Management reaffirmed full-year adjusted operating income guidance at $2.035-$2.135 billion and narrowed the range, according to the supplied analysis.
Key takeaways
- Q3 results met expectations, while full-year adjusted operating income guidance was reaffirmed.
- Volume declined 1.5% year over year, with hurricane, flu season, and cyber-incident effects cited in the analysis.
- Management is investing in technology, AI, scheduling, and clinical research as longer-term efficiency and care initiatives.
- Integrated Kidney Care recorded a $21 million adjusted operating loss in Q3, and revenue timing remains unpredictable.
Management priorities
- Roll out the next-generation clinical platform and scheduling systems.
- Expand AI use cases and work with external AI providers.
- Advance middle-molecule clearance research and potential product launches.
- Develop risk-stratification and revenue-cycle automation initiatives.
Follow DVA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$179.25Current
$81Low
$191.58Average
$270High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 5, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Aug 7, 2026 |
| TD Cowen | Buy | Hold | Upgrade | Aug 7, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Aug 5, 2026 |
| UBS | Buy | Buy | Maintain | Jul 10, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | May 6, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Sep 10, 2025 |
| Bernstein | Market Perform | Market Perform | Maintain | May 15, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 23, 2023 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 29, 2021 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 6, 2020 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 24, 2020 |
| JP Morgan | Neutral | Neutral | Maintain | Dec 20, 2019 |
| Raymond James | Market Perform | Outperform | Downgrade | Nov 7, 2019 |
| Baird | Neutral | Neutral | Maintain | Nov 6, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Sep 11, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jan 4, 2018 |
| Citigroup | Buy | Neutral | Upgrade | Dec 11, 2017 |
| Jefferies | Hold | Buy | Downgrade | Jun 26, 2017 |
| Keybanc | Hold | Buy | Downgrade | Sep 17, 2014 |
| Atlantic Equities | Overweight | Overweight | Maintain | Oct 10, 2013 |
| Feltl & Co. | Buy | Buy | Maintain | Oct 31, 2012 |
| Bank oferica | Buy | Buy | Maintain | Apr 5, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $179.26. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $215 | $179.92 | +19.9% | Aug 7, 2026 |
| Raymond James | Analyst unavailable | $220 | $180.67 | +22.7% | Aug 7, 2026 |
| Oppenheimer | Analyst unavailable | $220 | $180.67 | +22.7% | Aug 7, 2026 |
| Deutsche Bank | Pito Chickering | $265 | $185.52 | +47.8% | Aug 5, 2026 |
| Barclays | Andrew Mok | $224 | $227.99 | +25.0% | Aug 5, 2026 |
| Truist Financial | Analyst unavailable | $250 | $235.58 | +39.5% | Jul 14, 2026 |
| UBS | Analyst unavailable | $270 | $229.48 | +50.6% | Jul 10, 2026 |
| Barclays | Analyst unavailable | $218 | $234.31 | +21.6% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $205 | $194.38 | +14.4% | May 8, 2026 |
| Barclays | Andrew Mok | $194 | $193.88 | +8.2% | May 7, 2026 |
| Deutsche Bank | Pito Chickering | $220 | $157.04 | +22.7% | May 6, 2026 |
| Truist Financial | Analyst unavailable | $158 | $144.42 | -11.9% | Feb 5, 2026 |
| UBS | Analyst unavailable | $190 | $134.73 | +6.0% | Feb 4, 2026 |
| Barclays | Analyst unavailable | $158 | $111.19 | -11.9% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $143 | $126.56 | -20.2% | Oct 30, 2025 |
| Truist Financial | David MacDonald | $140 | $123.36 | -21.9% | Oct 14, 2025 |
| Barclays | Andrew Mok | $149 | $127.89 | -16.9% | Oct 9, 2025 |
| Truist Financial | David MacDonald | $148 | $129.54 | -17.4% | Aug 8, 2025 |
| Bernstein | Lisa Bedell Clive | $184 | $142.4 | +2.6% | Feb 21, 2025 |
| Bank of America Securities | Kevin Fischbeck | $145 | $133.53 | -19.1% | Aug 7, 2024 |
| Barclays | Andrew Mok | $150 | $134.45 | -16.3% | May 6, 2024 |
| Barclays | Sarah James | $81 | $70.54 | -54.8% | Oct 31, 2022 |
| UBS | Andrew Mok | $117 | $93.1 | -34.7% | Aug 19, 2022 |
| Truist Financial | David MacDonald | $90 | $79.44 | -49.8% | Jun 28, 2022 |
Track every rating change on DVA the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationDaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities.…
Historical context
All DVA earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
Get the DVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-05T12:00:45.722066+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-05T12:00:45.719155+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-05. For educational purposes only; not investment advice.